Absorption enhancement of melanotan-l

Comparison of the caco-2 and rat in situ models

Narayanan Surendran, Sydney O. Ugwu, Linh D. Nguyen, Eric J. Sterling, Robert T Dorr, James Blanchard

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The overall objective of this research was to evaluate the potential of Melanotan-I (MT-I) for oral delivery in humans. An in vitro cell monolayer model (Caco-2) was used to screen the effect of certain absorption enhancers on the transport of MT-I. The enhancers used were dimethyl-βcyclodextrin (DMβCD), sodium tauro-dihydrofusidate (STDHF), and aprotinin, a protease inhibitor. In addition, the effect of the most promising enhancers on the bioavailability of MT-I was deter-mined using an in situ closed loop rat model. In the Caco-2 monolayer model, coadministration of MT-I with aprotinin produced a 2.4-fold increase in the trans-port of MT-I. No significant enhancement was seen with either DMβCD or STDHF. Thus, inhibition of degradation of MT-I by proteases appears to be the most promising approach for delivering MT-I via the oral route. Finally, an attempt was made to compare the transport data from the Caco-2 model to bioavailability data in the rat model. The trends observed for both models were comparable and the data from the rat studies were in good agreement with the results obtained with the Caco-2 model.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalDrug Delivery
Volume2
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Aprotinin
Cyclodextrins
Biological Availability
Sodium
Protease Inhibitors
Peptide Hydrolases
Research
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Absorption enhancement of melanotan-l : Comparison of the caco-2 and rat in situ models. / Surendran, Narayanan; Ugwu, Sydney O.; Nguyen, Linh D.; Sterling, Eric J.; Dorr, Robert T; Blanchard, James.

In: Drug Delivery, Vol. 2, No. 1, 1995, p. 49-55.

Research output: Contribution to journalArticle

Surendran, N, Ugwu, SO, Nguyen, LD, Sterling, EJ, Dorr, RT & Blanchard, J 1995, 'Absorption enhancement of melanotan-l: Comparison of the caco-2 and rat in situ models', Drug Delivery, vol. 2, no. 1, pp. 49-55. https://doi.org/10.3109/10717549509031351
Surendran, Narayanan ; Ugwu, Sydney O. ; Nguyen, Linh D. ; Sterling, Eric J. ; Dorr, Robert T ; Blanchard, James. / Absorption enhancement of melanotan-l : Comparison of the caco-2 and rat in situ models. In: Drug Delivery. 1995 ; Vol. 2, No. 1. pp. 49-55.
@article{188b63c03c354d1db23e0362162fe02c,
title = "Absorption enhancement of melanotan-l: Comparison of the caco-2 and rat in situ models",
abstract = "The overall objective of this research was to evaluate the potential of Melanotan-I (MT-I) for oral delivery in humans. An in vitro cell monolayer model (Caco-2) was used to screen the effect of certain absorption enhancers on the transport of MT-I. The enhancers used were dimethyl-βcyclodextrin (DMβCD), sodium tauro-dihydrofusidate (STDHF), and aprotinin, a protease inhibitor. In addition, the effect of the most promising enhancers on the bioavailability of MT-I was deter-mined using an in situ closed loop rat model. In the Caco-2 monolayer model, coadministration of MT-I with aprotinin produced a 2.4-fold increase in the trans-port of MT-I. No significant enhancement was seen with either DMβCD or STDHF. Thus, inhibition of degradation of MT-I by proteases appears to be the most promising approach for delivering MT-I via the oral route. Finally, an attempt was made to compare the transport data from the Caco-2 model to bioavailability data in the rat model. The trends observed for both models were comparable and the data from the rat studies were in good agreement with the results obtained with the Caco-2 model.",
author = "Narayanan Surendran and Ugwu, {Sydney O.} and Nguyen, {Linh D.} and Sterling, {Eric J.} and Dorr, {Robert T} and James Blanchard",
year = "1995",
doi = "10.3109/10717549509031351",
language = "English (US)",
volume = "2",
pages = "49--55",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Absorption enhancement of melanotan-l

T2 - Comparison of the caco-2 and rat in situ models

AU - Surendran, Narayanan

AU - Ugwu, Sydney O.

AU - Nguyen, Linh D.

AU - Sterling, Eric J.

AU - Dorr, Robert T

AU - Blanchard, James

PY - 1995

Y1 - 1995

N2 - The overall objective of this research was to evaluate the potential of Melanotan-I (MT-I) for oral delivery in humans. An in vitro cell monolayer model (Caco-2) was used to screen the effect of certain absorption enhancers on the transport of MT-I. The enhancers used were dimethyl-βcyclodextrin (DMβCD), sodium tauro-dihydrofusidate (STDHF), and aprotinin, a protease inhibitor. In addition, the effect of the most promising enhancers on the bioavailability of MT-I was deter-mined using an in situ closed loop rat model. In the Caco-2 monolayer model, coadministration of MT-I with aprotinin produced a 2.4-fold increase in the trans-port of MT-I. No significant enhancement was seen with either DMβCD or STDHF. Thus, inhibition of degradation of MT-I by proteases appears to be the most promising approach for delivering MT-I via the oral route. Finally, an attempt was made to compare the transport data from the Caco-2 model to bioavailability data in the rat model. The trends observed for both models were comparable and the data from the rat studies were in good agreement with the results obtained with the Caco-2 model.

AB - The overall objective of this research was to evaluate the potential of Melanotan-I (MT-I) for oral delivery in humans. An in vitro cell monolayer model (Caco-2) was used to screen the effect of certain absorption enhancers on the transport of MT-I. The enhancers used were dimethyl-βcyclodextrin (DMβCD), sodium tauro-dihydrofusidate (STDHF), and aprotinin, a protease inhibitor. In addition, the effect of the most promising enhancers on the bioavailability of MT-I was deter-mined using an in situ closed loop rat model. In the Caco-2 monolayer model, coadministration of MT-I with aprotinin produced a 2.4-fold increase in the trans-port of MT-I. No significant enhancement was seen with either DMβCD or STDHF. Thus, inhibition of degradation of MT-I by proteases appears to be the most promising approach for delivering MT-I via the oral route. Finally, an attempt was made to compare the transport data from the Caco-2 model to bioavailability data in the rat model. The trends observed for both models were comparable and the data from the rat studies were in good agreement with the results obtained with the Caco-2 model.

UR - http://www.scopus.com/inward/record.url?scp=0028914940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028914940&partnerID=8YFLogxK

U2 - 10.3109/10717549509031351

DO - 10.3109/10717549509031351

M3 - Article

VL - 2

SP - 49

EP - 55

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 1

ER -